partnerships

September 9, 2020

Huadong Medicine and Exscientia enter co-development partnership to accelerate oncology drug discovery through artificial intelligence

First project in partnership will focus on the discovery of novel therapies for areas of DNA damage repair.

Exscientia, the world-leading, clinical-stage Artificial Intelligence (AI) drug discovery company and Huadong Medicine, the leading Chinese pharmaceutical company, announced today that the companies have entered into a co-development partnership to accelerate the discovery of breakthrough small-molecule therapeutics targeted at innovative approach to oncology. The first project selected in partnership is focused on transcription control of DNA damage response genes, to treat patients with defective DNA damage repair mechanism, leading to high mutation frequency, as seen is in patients with ovarian cancer and breast cancer.

Under this collaboration, the pharmatech Exscientia and Huadong will share responsibilities, with Exscientia applying its advanced Centaur Chemist(TM) AI platform to design new molecules against project specific objectives and Huadong Medicine applying its China based experimental and managerial capabilities to generate data and progress Exscientia’s AI design in a rapid closed-loop cycle.

Huadong Medicine Co., Ltd (SZSE 000963), ranked in the top 10 Chinese pharmaceutical companies by Forbes 2020, with more than 10,000 employees and over US $4 Billion annual revenue. The co- development partnership will support both Huadong’s strategy to introduce new medicines in key markets and Exscientia’s aims to advance AI-designed innovative medicines globally.

“This collaboration marks a key step for Huadong on its journey to become an innovation-based pharmaceutical company. We are pleased to work with Exscientia and are fully committed to make this collaboration a success.”, said Lyu Liang, Chairman of Huadong.

Professor Andrew Hopkins, CEO of Exscientia, said, “We are very excited to enter the partnership with Huadong Medicine. This innovative partnership provides strategic benefits to Huadong Medicine and Exscientia. We see this as the start of a long-term productive relationship to accelerate novel drug discovery and bring benefits to patients around the globe.”

About Huadong

Huadong Medicine Co., Ltd. was established in 1993 and headquartered in Hangzhou, Zhejiang Province, went public on the Shenzhen Stock Exchange (SZ.000963) in 1999. Huadong is a leading Chinese pharmaceutical company with integrated R&D, manufacture, marketing, sales, distribution and logistics and focuses on R&D, production and sales of medication for specialist departments, chronic diseases and special medicine. Huadong has formed core product pipelines in such fields as chronic kidney diseases, transplantation immunity, endocrinology and digestive system, and owns a number of first-line clinical medications with market advantages in China. Huadong has more than 10,000 employees and sales force covers nearly 30,000 hospitals in China. The R&D organization currently has more than 1000 FTEs involved in small molecule, biologics and polypeptide drugs, supporting drug discovery, preclinical research, clinical development, CMC and regulatory. For more details, please visit http://www.eastchinapharm.com/EnPhone/

About Exscientia

Exscientia is a global leading pharmatech company, using Artificial Intelligence (AI) to drive drug discovery. Founded in Scotland in 2012, Exscientia fuses the power of the original AI with the experience of seasoned drug hunters, Exscientia’s innovative Centaur Chemist(TM) platform enables breakthrough productivity gains as well as new approaches to improve drug design. Novel compounds are automatically designed and prioritized for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development. Exscientia’s Centaur Biologist(TM) platform drives the flexible analysis and prioritisation of discovery targets across all pharmaceutically relevant disease space. Exscientia is collaborating with several leading pharmaceutical and life sciences companies and is the first AI company to have designed a novel molecule to enter the clinic. Exscientia has its headquarters in Oxford, England with further offices in the Scotland, USA and Japan. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientialtd.

Contacts:

For Exscientia
Milly Xia Chen, Commercial Director
Mark Swindells, Chief Commercial Officer contact@exscientia.ai
Anitra Sprauten, Edelman anitra.sprauten@edelman.com +44 (0)78 9685 9386

For Huadong Medicine
Bo Chen pretor@eastchinapharm.com

华东医药与全球领先的人工智能药物发现公司 Exscientia 达成战略合作, 通过人工智能加速抗肿瘤药物研发

华东医药与世界领先的人工智能(AI)药物研发公司 Exscientia 今日宣布,双方已 建立合作开发伙伴关系,加速发现肿瘤领域小分子药物突破性的创新疗法。双方合作 的首个项目是针对 DNA 损伤应答基因转录控制的药物开发,治疗 DNA 损伤修复缺陷 的高突变频率的患者,如卵巢癌和乳腺癌患者等。

双方基于在人工智能和药物研发的资源与优势,加速小分子抗肿瘤药物的开发。 Exscientia 凭借其先进的 Centaur Chemist(TM) AI 平台进行自动化药物研发指导,设计特 定靶标的新分子;华东医药利用研发资源和管理能力,快速合成和实验检测以支持 AI 系统新一轮化合物的优化与筛选。

华东医药是 2020 年《福布斯》排名前十的上市医药企业(SZ.000963),拥有一万多 名员工,年销售额超过 40 亿美元。此次合作将加快华东医药创新药战略转型,也有助 于 Exscientia 全球推广 AI 设计创新药物。

华东医药董事长吕梁表示:“此次合作是华东医药在成为创新型制药公司的道路 上又向前迈出重要的一步。我们很高兴与 Exscientia 达成此次战略合作,我们将发挥各 自的研发优势,促成项目取得成功。”

Exscientia 首席执行官安德鲁·霍普金斯说:“我们很高兴能与华东医药建立合作伙 伴关系,这种创新的合作模式符合 Exscientia 和华东医药的战略利益。我们认为这也是 长期合作关系的开始,双方将加速新药研发,造福全球患者。”

关于华东医药

华东医药股份有限公司成立于 1993 年,总部位于浙江杭州,1999 年在深圳证券交易所 上市(000963)。华东医药是一家集研发、生产、营销、分销和物流为一体的中国医药 企业。华东医药深耕专科、慢病用药及特殊用药领域的研发、生产和销售,形成慢性 肾病、移植免疫、内分泌、消化系统等领域为核心的产品管线,拥有多个在国内具有 市场优势的一线临床用药。华东医药在中国拥有一万多名员工,销售能力覆盖三万家 医院,拥有 1000 多名研发人员,涉及小分子、大分子和多肽药物,涵盖药物发现、临

床前研究、临床研究、CMC 及注册的各个研发环节。更多信息请访问: http://www.eastchinapharm.com/EnPhone/

关于 Exscientia

Exscientia 是一家世界领先的人工智能(AI)驱动的药物发现公司,于 2012 年在英国注册 成立。通过将人工智能的力量与经验丰富的药物科学家相结合,Exscientia 的创新 Centaur Chemist(TM)平台可以实现突破性的药物开发效率,新型化合物由人工智能系统 自动设计并优先用于合成,迅速将化合物推进达到临床开发所需的候选化合物标准。

Exscientia 公司的 Centaur Biologist(TM)平台可在所有与药物相关的疾病领域内灵活地分析 发现目标并确定其优先级。Exscientia 正在与几家领先的制药和生命科学公司合作,是 首家设计出新型分子进入临床的人工智能公司。Exscientia 总部设在牛津,并在英国、 美国和日本设有办事处。更多信息请访问 www.exscientia.ai 或关注推特@exscientialtd 。

Contacts:

For Exscientia
Milly Xia Chen, Commercial Director
Mark Swindells, Chief Commercial Officer
contact@exscientia.ai

Anitra Sprauten, Edelman anitra.sprauten@edelman.com +44 (0)78 9685 9386

For Huadong Medicine
Bo Chen pretor@eastchinapharm.com

focus on the discovery of novel therapies for DNA damage repair.